These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38933451)

  • 1. Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience.
    Vlachou E; Johnson BA; McConkey D; Jing Y; Matoso A; Hahn NM; Hoffman-Censits J
    Front Oncol; 2024; 14():1377842. PubMed ID: 38933451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature.
    Vlachou E; Matoso A; McConkey D; Jing Y; Johnson BA; Hahn NM; Hoffman-Censits J
    Eur Urol Open Sci; 2023 Mar; 49():100-103. PubMed ID: 36820243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
    Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
    Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic alterations of
    Jindal T; Zhu X; Bose R; Kumar V; Maldonado E; Deshmukh P; Shipp C; Feng S; Johnson MS; Angelidakis A; Kwon D; Borno HT; de Kouchkovsky I; Desai A; Aggarwal R; Fong L; Small EJ; Wong A; Porten S; Chou J; Friedlander T; Koshkin VS
    Front Oncol; 2023; 13():1161089. PubMed ID: 37091148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 Jul; 19(4):635-644. PubMed ID: 38807017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Minato A; Kimuro R; Ohno D; Tanigawa K; Kuretake K; Matsukawa T; Takaba T; Jojima K; Harada M; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N; Miyamoto H
    Anticancer Res; 2023 Sep; 43(9):4055-4060. PubMed ID: 37648337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
    Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
    Furubayashi N; Minato A; Tomoda T; Masaoka H; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Song Y; Harada K; Kuroiwa K; Seki N; Fujimoto N; Nakamura M;
    Anticancer Res; 2024 Jul; 44(7):3025-3032. PubMed ID: 38925809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Matsubara N; Yonese J; Kojima T; Azuma H; Matsumoto H; Powles T; Rosenberg JE; Petrylak DP; Matsangou M; Wu C; Campbell M; Yamashiro M
    Cancer Med; 2023 Feb; 12(3):2761-2771. PubMed ID: 36052536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study.
    Hayakawa N; Kikuchi E; Kaneko G; Yamashita R; Ikarashi D; Endo Y; Usui K; Obara W; Oyama M; Kondo Y
    Jpn J Clin Oncol; 2024 Nov; 54(11):1194-1200. PubMed ID: 38943559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
    Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
    Hoffman-Censits J; Maldonado L
    Onco Targets Ther; 2022; 15():1519-1529. PubMed ID: 36545447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.
    Zuo P; Bonate P; Garg A; Matsangou M; Tang M
    Clin Pharmacol Ther; 2024 Nov; 116(5):1278-1288. PubMed ID: 39039635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.
    Nakane K; Taniguchi K; Nezasa M; Enomoto T; Yamada T; Tomioka-Inagawa R; Niwa K; Tomioka M; Ishida T; Nagai S; Yokoi S; Taniguchi T; Kawase M; Kawase K; Iinuma K; Tobisawa Y; Koie T
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.